

Guest editorial

Ganoderma lucidum in cancer research

Ganoderma lucidum, popular medicinal mushroom, has been used as a home remedy in traditional Chinese medicine (TCM) in many Asian countries during the past two millennia [1]. The regular consumption of *G. lucidum* in the form of tea or mushroom powder was believed to preserve the human vitality and to promote longevity [2]. *G. lucidum* has been also used for the prevention or treatment of a variety of diseases including cancer [3]. Western medicine started to accept natural product from the TCM and the popularity of herbal therapies for the treatment of cancer have been recently increasing in the United States [4]. Therefore, scientific justification based on the elucidation of mechanisms responsible for the biological effects of these natural products could help for their validation in alternative or adjuvant cancer therapies. The anticancer effects of *G. lucidum* were associated with triterpenes [5], polysaccharides [6,7], or immunomodulatory proteins [8], through the mechanisms involving inhibition of DNA polymerase [9], inhibition of post-translational modification of the Ras oncoprotein [10], or the stimulation of cytokine production [11]. Moreover, *G. lucidum*: (i) inhibits proliferation and invasive behavior of breast and prostate cancer cells through the down-regulation of expression of cyclin-D1 and suppression of secretion of urokinase-plasminogen activator (uPA) [12–14]; (ii) inhibits growth and induces apoptosis of breast and prostate cancer cells through the up-regulation of expression of p21 and Bax [15,16]; (iii) inhibits growth of hepatoma cells through the suppression of protein kinase C [17]; (iv) induces apoptosis of colon cancer cells by increasing the activity of caspase-3 [18]; (v) suppresses angiogenesis through the inhibition of secretion of vascular endothelial growth factor (VEGF) and transforming growth factor- β 1 (TGF- β 1) from prostate cancer cells [19].

In this issue of *Leukemia Research*, Müller et al. [20] evaluated the effects of *G. lucidum* on cancer cells of hematologic origin, and they found that *G. lucidum* inhibits proliferation and induces apoptosis in a variety of leukemia, lymphoma, and myeloma cells. Moreover, they showed that the inhibition of proliferation of acute myeloblastic leukemia HL-60 cells was associated with cell cycle arrest at G2/M phase and

apoptosis, whereas the inhibition of proliferation and apoptosis of lymphoma U937 was mediated by the up-regulation of expression of p21 and p27. Therefore, Müller et al. further increased our knowledge about the anticancer effects of *G. lucidum* on hematopoietic cells, and confirmed that *G. lucidum* inhibits distinct signaling pathways in different cancer cells. Finally, they used standardized *G. lucidum* extract containing 0.15% ganoderic acid C2. Although triterpenes or triterpenoid fractions from *G. lucidum* previously demonstrated anticancer effects in vitro as well as in vivo, it is uncertain if this amount of ganoderic acid could be responsible for the effect of *G. lucidum* on hematopoietic cells. Nevertheless, the standardization of *G. lucidum* is crucial for its characterization since the composition and amount of biologically active triterpenes depend on the places of the production, cultivation conditions, extraction procedures and the strains of *G. lucidum* [21]. As recently demonstrated, some extracts of *G. lucidum* markedly inhibited intracellular signaling and invasive behavior of cancer cells, whereas other extracts did not show any effect [22]. Thus, the standardization of *G. lucidum* is necessary for the acceptance of *G. lucidum* as a natural product suitable for the treatment of cancer.

The major obstacle for the acceptance of natural products in Western medicine is their complexity. However, this complexity can also bring significant advantages. For example, certain components in the natural products can reduce the cytotoxicity of the whole product, and the interaction between different biologically active components can be responsible for their in vivo effects [23]. In addition, different compounds can modulate unrelated signaling and therefore, can possess synergistic effect [24]. Thus, triterpenes in *G. lucidum* directly suppress growth and invasive behavior of cancer cells, whereas *G. lucidum* polysaccharides stimulate immune system resulting in the production of cytokines and activation of anti-cancer activities of immune cells [5,25]. In conclusion, although the data from the recent studies demonstrating the effect of *G. lucidum* on the molecular level are promising, preclinical and clinical studies with *G. lucidum* are necessary for the validation of this natural product in the prevention and/or therapy of cancer.

References

- [1] Yun TK. Update from Asia. Asian studies on cancer chemoprevention. *Ann N Y Acad Sci* 1999;889:157–92.
- [2] Shiao MS, Lee KR, Lin LJ, Wang CT. Natural products and biological activities of the Chinese medical fungus, *Ganoderma lucidum*. In: Ho CT, Osawa T, Huang MT, Rosen RT, editors. Food phytochemicals for cancer prevention. II. Teas, spices, and herbs. Washington, DC: American Chemical Society; 1994. p. 342–54.
- [3] Sliva D. Cellular and physiological effects of *Ganoderma lucidum* (Reishi). *Mini-Rev Med Chem* 2004;4:873–9.
- [4] Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. *JAMA* 1998;280:1569–75.
- [5] Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of *Ganoderma lucidum* and their cytotoxicity against meth-A and LLC tumor cells. *Chem Pharm Bull* 2000;48:1026–33.
- [6] Miyazaki T, Nishijima M. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of *Ganoderma lucidum*. *Chem Pharmacol Bull* 1981;29:3611–6.
- [7] Sone Y, Okuda R, Wada N, Kishida E, Misaki A. Structures and anti-tumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of *Ganoderma lucidum*. *Agric Biol Chem* 1985;49:2641–53.
- [8] Lin WH, Hung CH, Hsu CI, Lin JY. Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from *Ganoderma tsugae* (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. *J Biol Chem* 1997;272:20044–8.
- [9] Mizushima Y, Hanashima L, Yamaguchi T, Takemura M, Sugawara F, Saneyoshi M, et al. A mushroom fruiting body-inducing substance inhibits activities of replicative DNA polymerases. *Biochem Biophys Res Commun* 1998;249:17–22.
- [10] Lee S, Park S, Oh JW, Yang C. Natural inhibitors for protein prenyltransferase. *Planta Med* 1998;64:303–8.
- [11] Wang SY, Hsu ML, Hsu HC, Lee SS, Shiao MS, Ho CK. The anti-tumor effect of *Ganoderma lucidum* is mediated by cytokines released from activated macrophages and T lymphocytes. *Int J Cancer* 1997;70:699–705.
- [12] Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd Jr FP, Ho NWY. *Ganoderma lucidum* suppresses motility of highly invasive breast and prostate cancer cells. *Biochem Biophys Res Commun* 2002;298:603–12.
- [13] Slivova V, Valachovicova T, Jiang J, Sliva D. *Ganoderma lucidum* inhibits invasiveness of breast cancer cells. *J Cancer Integr Med* 2004;2:25–30.
- [14] Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. *Ganoderma lucidum* suppresses growth of breast cancer cells through the inhibition of Akt/NF- κ B signaling. *Nutr Cancer* 2004;49:209–16.
- [15] Hu H, Ahn NS, Yang X, Lee YS, Kang KS. *Ganoderma lucidum* extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. *Int J Cancer* 2002;102:250–3.
- [16] Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. *Ganoderma lucidum* inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. *Int J Oncol* 2004;24:1093–100.
- [17] Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from *Ganoderma lucidum* inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. *Life Sci* 2003;72:2381–90.
- [18] Hong KJ, Dunn DM, Shen CL, Pence BC. Effects of *Ganoderma lucidum* on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. *Phytother Res* 2004;18:768–70.
- [19] Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. *Ganoderma lucidum* suppresses angiogenesis through the inhibition of secretion of VEGF and TGF- β 1 from prostate cancer cells. *Biochem Biophys Res Commun* 2005;330:46–52.
- [20] Müller CI, Kumagai T, O'Kelly J, Seeram NP, Heber D, Koeffler HP. *Ganoderma lucidum* causes apoptosis in leukemia, lymphoma and multiple myeloma cells. *Leuk Res* 2006;30:841–8.
- [21] Hattori M. Recent studies on the bitter principles of *Ganoderma lucidum*—isolation of novel triterpenes, their biological activity and pharmacokinetics. In: Proceedings of international symposium of Ganoderma science. 2001.
- [22] Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd Jr FP, Ho NWY. Biologic activity of *Ganoderma lucidum* for the inhibition of highly invasive breast and prostate cancer cells. *J Altern Complement Med* 2003;9:491–7.
- [23] Wilasumee C, Kittur S, Siddiqui J, Bruch D, Wilasumee S, Kittur DS. In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes. *J Altern Complement Med* 2002;8:467–75.
- [24] Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine* 2001;8:401–9.
- [25] Lin ZB. Cellular and molecular mechanisms of immuno-modulation by *Ganoderma lucidum*. *J Pharmacol Sci* 2005;99:144–53.

Daniel Sliva*

Cancer Research Laboratory, Methodist Research
Institute, 1800 North Capitol Ave., E504,
Indianapolis, IN 46202, United States

*Tel.: +1 317 962 5731; fax: +1 317 962 9369.

E-mail address: dsliva@clarian.org

23 December 2005

Available online 3 February 2006